An audit of genetic referral outcomes at the time of diagnosis of breast cancer

Abstract

Introduction: Mutations in BRCA1 and BRCA2 account for 5-10% of all female breast cancers, and 15-20% of familial breast cancers. Identifying these mutations at diagnosis can aid shared decision-making in the surgical and oncological setting. NICE guidance recommends referral of high-risk patients to a specialist genetic clinic. This study aims to assess results of genetic testing at diagnosis and time taken for receiving results.